Nomlabofusp (CTI-1601)

About Larimar Therapeutics

Larimar Therapeutics is a focused, clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases, with an initial focus on Friedreich's ataxia. Its core achievement is the advancement of nomlabofusp (CTI-1601), a recombinant fusion protein designed to address the root cause of Friedreich's ataxia by delivering frataxin to mitochondria, now in Phase 2 development. The company's strategy leverages a proprietary intracellular delivery platform to create targeted protein replacement therapies, aiming to build a pipeline for monogenic rare diseases. Larimar went public in 2021 and operates as a lean organization concentrating resources on translating its platform into validated clinical outcomes.

Therapeutic Areas

Other Friedreich's Ataxia Drugs